Disc Medicine (IRON) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Disc Medicine (IRON) is Moderate Underperform.

The composite score behind that read is -0.21, weighing +0.05 of bullish evidence against -0.24 bearish.

Disc Medicine last closed at $63.33, -1.83% on the session.

Against the IVW growth benchmark the position is -2.75% over the forecast window.

The read is built from 12 underlying insights — 3 bullish and 9 bearish.

Agreement across those insights is 75%.

14 graded predictions for IRON so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Disc Medicine in the 21st percentile on return on equity, where 100 is best.

Disc Medicine is classified under Health Care / Biotechnology, with a market capitalisation of $2.48B.

StockMap tracks Disc Medicine as the 73rd largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite Disc Medicine ranks 167th of 344 in the group, against a group median of -0.21.